The latest price target for Elevance Health (NYSE:ELV) was reported by Argus Research on January 29, 2025. The analyst firm set a price target for $405.40 expecting ELV to rise to within 12 months (a possible 5.27% upside). 46 analyst firms have reported ratings in the last year.

The latest analyst rating for Elevance Health (NYSE:ELV) was provided by Argus Research, and Elevance Health reiterated their hold rating.

The last upgrade for Elevance Health Inc happened on April 27, 2023 when Morgan Stanley raised their price target to $571. Morgan Stanley previously had an equal-weight for Elevance Health Inc.

The last downgrade for Elevance Health Inc happened on October 18, 2024 when Argus Research changed their price target from N/A to N/A for Elevance Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevance Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevance Health was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.

While ratings are subjective and will change, the latest Elevance Health (ELV) rating was a reiterated with a price target of $405.40 to $405.40. The current price Elevance Health (ELV) is trading at is $385.10, which is out of the analyst’s predicted range.